Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus for at least 12 months~* Current treatment with any basal bolus insulin for at least 12 months~* HbA1c below or equal to 10.0%~* BMI (Body Mass Index) below or equal to 35.0 kg/m\^2~* For the extension trial only: Completion of the 52 week treatment period in trial NN1250-3583 (NCT00982228)~Exclusion Criteria:~* Use of any other antidiabetic drug than insulin within the last 3 months~* Cardiovascular disease within the last 6 months~* Uncontrolled treated/untreated severe hypertension~* Recurrent severe hypoglycemia or hypoglycemic unawareness or hospitalisation for diabetic ketoacidosis during the previous 6 months~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements~* Cancer and medical history of cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD (Type: EXPERIMENTAL): None
- IGlar OD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).